ZG 170607
Alternative Names: ZG-170607Latest Information Update: 06 Jan 2023
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Class Antineoplastics; Heterocyclic compounds; Imidazoles; Quinolines; Small molecules
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 Dec 2022 Preclinical development is still ongoing for Solid tumours in China (Suzhou Zelgen Biopharmaceuticals pipeline, December 2022)